Journal
DERMATOLOGY AND THERAPY
Volume 10, Issue 6, Pages 1185-1198Publisher
ADIS INT LTD
DOI: 10.1007/s13555-020-00447-y
Keywords
Cytokines; Disease progression; Emerging treatments; JAK; Maintenance therapy; Melanocyte; Regeneration; Resident memory; T cells; Vitiligo
Categories
Ask authors/readers for more resources
Vitiligo is a chronic inflammatory skin disease leading to the loss of epidermal melanocytes. To date, treatment options for vitiligo patients are limited, lack sustained efficacy, and are mainly based on off-label use of immunosuppressive agents, such as systemic or topical steroids or topical calcineurin inhibitors, in association with the use of ultraviolet light. However, recent insights into the understanding of the immune pathogenesis of the disease have led to the identification of several therapeutic targets and the development of targeted therapies that are now being tested in clinical trials. In this review, based on the physiopathology of the disease, we summarize emerging targets that could be developed for the treatment of vitiligo and discuss recent and ongoing developments of drugs for the management of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available